IRulya Therapeutics Inc. IRLA
Set alert
33.03 USD -0.48 -1.42%
As of Nov 2, 3:48 PM ET
31.02 Day range 33.72
15.10 52-week range 910.00
- YTD
- -95.07%
- 1 year
- -89.99%
- Open
- 32.97
- Prev close
- 33.50
- Mkt cap
- 33.59M
- Vol
- 92.39K
- Avg vol
- 43.40K
- EPS
- -214.01
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 31.02
- High
- 33.72
30m chart
Built from the cached five-day intraday bars.
Signals (11)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 3:10 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 1:05 PM | 3 days ago |
| SMA: Bullish | Oct 30, 11:00 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:45 AM | 3 days ago |
| SMA: Bullish | Oct 29, 3:55 PM | 4 days ago |
| SMA: Bearish | Oct 29, 11:50 AM | 4 days ago |
| SMA: Bullish | Oct 28, 2:50 PM | 5 days ago |
| SMA: Bearish | Oct 28, 9:50 AM | 5 days ago |
| SMA: Bullish | Oct 27, 12:15 PM | 6 days ago |
| SMA: Bearish | Oct 27, 11:25 AM | 6 days ago |
| SMA: Bullish | Oct 27, 10:40 AM | 6 days ago |
Financials — quick view
IRLA Revenue — quarterly 0
IRLA Net income — quarterly -75.49M
IRLA EPS — quarterly -12.31
News
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- IRulya Therapeutics to Participate in the Craig-Hallum Biotech Catalyst Conference
- Quince Therapeutics (NASDAQ: QNCX) renames itself IRulya and sets IRLA ticker
- Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease
- Quince Therapeutics Stockholders Approve PIPE, Share Increase and Equity Plans
- Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript
- Quince Therapeutics, Inc. (QNCX) Discusses LAM-001 Clinical Progress in Pulmonary Hypertension and Bronchiolitis Obliterans Syndrome Transcript
- Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026
- Quince Therapeutics to Participate in September 2026 Investor Conferences
- Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update
Your note
Sign in to keep a note on IRLA — it syncs with the Stock Master app.